Kanna Health announces FDA and MHRA approvals to begin its Phase 1 clinical trial for the development of KH-001 as first FDA-approved treatment for premature ejaculation
07.08.2025 - 18:06:01 | prnewswire.co.uk
Kanna Health Ltd Austria Belgium France Germany Italy Netherlands Spain Switzerland United Kingdom United States of America England
